Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Tavanta Therapeutics

Next Previous
Drug Profile

Abiraterone acetate - Tavanta Therapeutics

Alternative Names: DRGT 45; TAVT-45

Latest Information Update: 14 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Druggability Technologies
  • Developer Tavanta Therapeutics
  • Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 14 Feb 2026 Abiraterone acetate is still in phase-III trial in Prostate cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA, United Kingdom, Sweden, Spain, Puerto Rico, Poland, Hungary, France (PO) (NCT04887506)
  • 02 Jun 2023 Efficacy and adverse events data from phase-III trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 09 Jan 2023 Tavanta Therapeutics plans to launch TAVT 45 in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top